Mediwound (MDWD) versus CV Sciences (OTCMKTS:CVSI) Head to Head Survey

CV Sciences (OTCMKTS:CVSI) and Mediwound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CV Sciences and Mediwound, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CV Sciences 0 0 2 0 3.00
Mediwound 0 0 2 0 3.00

CV Sciences presently has a consensus target price of $8.50, suggesting a potential upside of 74.90%. Mediwound has a consensus target price of $13.00, suggesting a potential upside of 192.13%. Given Mediwound’s higher probable upside, analysts plainly believe Mediwound is more favorable than CV Sciences.

Risk and Volatility

CV Sciences has a beta of -0.93, suggesting that its share price is 193% less volatile than the S&P 500. Comparatively, Mediwound has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.


This table compares CV Sciences and Mediwound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CV Sciences N/A -0.01% -0.01%
Mediwound -31.08% -398.49% -35.79%

Valuation and Earnings

This table compares CV Sciences and Mediwound’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CV Sciences $48.24 million 10.09 $10.00 million $0.09 54.00
Mediwound $3.40 million 35.57 -$1.06 million ($0.49) -9.08

CV Sciences has higher revenue and earnings than Mediwound. Mediwound is trading at a lower price-to-earnings ratio than CV Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.2% of CV Sciences shares are held by institutional investors. Comparatively, 30.3% of Mediwound shares are held by institutional investors. 10.1% of CV Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


CV Sciences beats Mediwound on 8 of the 12 factors compared between the two stocks.

CV Sciences Company Profile

CV Sciences, Inc. operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. This segment provides its hemp extract products in balms, sprays, drops, capsules, gummies, and softgel forms. It also sells raw materials to various customers that produce products for resale into the market in Europe. The Specialty Pharmaceuticals segment develops cannabinoids to treat a range of medical indications. Its product candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with's FREE daily email newsletter.